Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine whether the combination of bendamustine and bortezomib in patients with indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia is safe and tolerable.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Peter Moosmann
Collaborators
NCT02682667 · Multiple Myeloma, Lymphoma, Non-Hodgkin, and more
NCT01676805 · Hodgkin Disease, Lymphoma, Non-Hodgkin, and more
NCT06923397 · Lymphoma, Lymphoma, Hodgkin, and more
NCT06510361 · Lymphoma, Follicular Lymphoma, and more
NCT05442515 · B-NHL, B-Non Hodgkin Lymphoma, and more
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions